Nice read published on MedPage Today about ISA’s phase 2 trial with our lead product ISA101, led by Bonnie Glisson.
Investigators from the University of Texas MD Anderson Cancer Center assessed the potential synergy between tumor-specific vaccine ISA101 and anti–PD-1 immune checkpoint antibody (nivolumab) in patients with incurable HPV-16–positive cancer.
ecancer interviewed ISA’s Chief Science Officer Prof. Dr. Kees Melief on his views on cancer vaccines during the AACR annual meeting 2019 in Atlanta.
Prof. Melief discusses the favourability of cancer vaccines. Cancer vaccines can be easily applied to large numbers of patients and are low in cost. When combined with chemotherapy and immunotherapy they can have great benefit.
He also speaks about ISA’s latest study looking at the HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer.
In Atlanta Prof. Melief received the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019.
Cornelis J. M. ‘Kees’ Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the American Association for Cancer Research (AACR) and Cancer Research Institute (CRI) during the 2019 AACR Annual Meeting.
Dr. Melief, a member of the CRI Scientific Advisory Council and CLIP Grant Review Committee, is being honored for his work on the development of effective immunotherapies for virus-induced tumors, including a novel vaccine strategy that uses synthetic long peptides (SLP) to target cancers associated with infection by the human papilloma virus (HPV). Arthur N. Brodsky, Ph D. interviewed